SCHEMBL4965348

SCHEMBL4965348

CC(C)=C1ON=C(C(C(C)C)N(CCCN)C(=O)c2ccc(C)cc2)N(Cc2ccccc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 18/20 0.56
KIF23 Q02241 1/20 0.56
MAP1LC3B Q9GZQ8 2/20 0.54
HTT P42858 1/20 0.54
KCNH2 Q12809 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965044 0.89 MAP1LC3B (0.53) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4965048 0.89 MAP1LC3B (0.53) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4586189 0.86 MAP1LC3B (0.58) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4966633 0.84 MAP1LC3B (0.57) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4965354 0.79 KIF11 (0.44) KIF11KIF23MAP1LC3BKCNH2CYP3A4
SCHEMBL4586381 0.79 MAP1LC3B (0.57) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4498513 0.77 KIF11 (0.66) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4968235 0.76 KIF11 (0.65) KIF11KIF23MAP1LC3BHTTKCNH2
SCHEMBL4376437 0.76 KIF11 (0.78) KIF11KIF23MAP1LC3BKCNH2CYP3A4
SCHEMBL14242968 0.76 KIF11 (0.57) KIF11KIF23MAP1LC3BHTTKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622883-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2008-04-02 EP claimed
US-20070232597-A1 Compounds, Compositions, and Methods CYTOKINETICS, INC. 2007-10-04 US claimed
EP-1622883-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2006-02-08 EP claimed
WO-2004091547-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC (US) 2004-10-28 WO claimed
EP-1622883-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2008-04-02 EP disclosed
US-20070232597-A1 Compounds, Compositions, and Methods CYTOKINETICS, INC. 2007-10-04 US disclosed
US-20070232597-A1 Compounds, Compositions, and Methods CYTOKINETICS, INC. 2007-10-04 US disclosed
US-20070232597-A1 Compounds, Compositions, and Methods CYTOKINETICS, INC. 2007-10-04 US disclosed
EP-1622883-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2006-02-08 EP disclosed
WO-2004091547-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232597-A1 Compounds, Compositions, and Methods ALPP, PCNA, MKI67 KIF11 538/4885KIF23 246/4885MAP1LC3B 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.